The NRL says suspended winger Sandor Earl faces allegations of multiple league anti-doping rule violations, including a number of trafficking claims.

Chief operating officer Jim Doyle says the NRL’s anti-doping tribunal will be convened to offer Earl a hearing to determine the charges.

It comes after Earl’s lawyer Tim Unsworth told ABC TV’s 7.30 on Monday night that the Australian Sports Anti Doping Authority (ASADA) had placed Earl on its register of findings, but had omitted a previous allegation that he trafficked the peptide CJC-1295 while injured in 2011.

Doyle said on Tuesday that Earl had admitted injecting CJC-1295 on many occasions in 2011.

Further, in the tribunal, Doyle said he faced allegations of NRL anti-doping rule violations of trafficking or attempted trafficking in other prohibited substances including the growth hormone Somatropin, Selective Androgen Receptor Modulators (SARMS), the anabolic agent Clenbuterol and the testosterone blend Sustanon during 2012 and 2013.

Doyle acknowledged ASADA had “at this time elected not to record an allegation of trafficking of the banned peptide CJC 1295 on its register of findings”.

The NRL anti-doping policy provides for penalties of maximum two-year bans for using banned substances and from four years to lifetime bans for trafficking or attempted trafficking.

MORE TO COME